Sun Pharmaceutical Industries Limited has responded to a news item published on news18.com on January 19, 2026, with the headline "Sun Pharma Eyes Stronger US Presence with USD 10 Billion Organon Acquisition". The company stated that the information presented in the article is speculative in nature and does not constitute a material event or information that requires disclosure under Regulation 30 of the Listing Regulations.

Sun Pharma emphasized its adherence to the highest standards of corporate governance and disclosures, assuring that it will promptly inform the stock exchanges of any material events as mandated. The company also noted that a similar clarification was sought by BSE Limited and its response has been filed and made available in the public domain.